Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc (NQ: COSM )

1.030 -0.020 (-1.90%)
Streaming Delayed Price Updated: 11:00 AM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cosmos Health Inc

< Previous 1 2 3 4 Next >
Cosmos Health to Participate at Capital Link’s 'Invest in Greece' Forum in New York
Via ACCESSWIRE
Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers
Via ACCESSWIRE
Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product
Via ACCESSWIRE
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
Via ACCESSWIRE
Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders
Via ACCESSWIRE
COSMOS HEALTH CEO Issues Letter to Shareholders
Via ACCESSWIRE
Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company
Via ACCESSWIRE
Cosmos Health Announces Expansion of Its C-Sept Brand with the Launch of C-Scrub Wash; Capitalizing on $29 Billion Global Antiseptic and Disinfectant Market
Via ACCESSWIRE
Cosmos Health Announces Relaunch of bio-bebe(R), its Proprietary Organic Infant Care &amp; Nutrition Brand; Aims to Penetrate $103bn Global Baby Food Market
Via ACCESSWIRE
Cosmos Health Announces Strategic Collaboration with C.A.PAPAELLINAS Group
Via ACCESSWIRE
Cosmos Health Starts Stock Buyback Program
Via ACCESSWIRE
BestGrowthStocks.com issues New Growth Report on Cosmos Health
NEW YORK, NY / NewsDirect / September 13th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks... 
Via TheNewswire.com
Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023
Via ACCESSWIRE
Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04
Via ACCESSWIRE
Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor
Via ACCESSWIRE
Cosmos Health Continues to Expand Mediterranation Brand, Welcomes Eleonas and Olympus Mons; Boosts Exports and Secures Purchase Orders, Including from Leading Multinational Health Food Chain
Via ACCESSWIRE
Cosmos Health Provides Update on Recent Developments, Maintains Strong Financial Position, Reaffirms Commitment to Growth, and Highlights CEO's Continued Investment Now Exceeds $15 Million
Via ACCESSWIRE
Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
Cosmos Health Inc. Announces Pricing of $5.25 Million Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
Cosmos Health Successfully Completes Acquisition of Cana Laboratories; Anticipates to Record a Substantial Gain on Bargain Purchase
Via ACCESSWIRE
Cosmos Health Launches Chios Island, the Latest Addition to Its Mediterranation Premium Line of Supplements
Via ACCESSWIRE
Cosmos Health Successfully Completes Second Phase of CCX0722 Development, an Innovative Product for Obesity and Weight Management: Significant Step in Bringing Product to the Multi-Billion-Dollar Market
Via ACCESSWIRE
Cosmos Health Successfully Closes Acquisition of Assets from I. Bikas GP; Annual Revenue Projected to Grow by over $10 Million
Via ACCESSWIRE
Cosmos Health Expands Premium Nutritional Supplements Line Mediterranation with the Launch of Terra Creta
Via ACCESSWIRE
Cosmos Health set to join Russell Microcap Index
Via ACCESSWIRE
Cosmos Health Enters into Binding Letter of Intent for the Acquisition of Docpharm GmbH., an Established German Pharmaceutical Distributor; Expected to Boost Our Annual Revenue by Approximately €32M, or 70%, by the End of 2025 vs FY 2022.
Via ACCESSWIRE
Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income
Via ACCESSWIRE
Cosmos Health Enters Final Phase for the Acquisition of Cana Laboratories Following Conclusion of Stock Purchase Agreement
Via ACCESSWIRE
Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders
Via ACCESSWIRE
Cosmos Health Ends 2022 with Transformed Balance Sheet and Achieves Positive Adjusted EBITDA for the Fiscal Year 2022
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.